Studies on the RAS gene family—KRAS, HRAS, and NRAS—have revealed the pivotal role of KRAS mutations in various cancers despite their relatively low frequency in breast cancer, emphasizing the untapped potential for precision treatments targeting this mutation [14,15]. Here, HRAS is linked to cancer.